- Home
- ADCT vs EHAB Comparison
ADCT vs EHAB Comparison
Compare ADCT & EHAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADCT
- EHAB
- Stock Information
- Founded
- ADCT 2011
- EHAB 2014
- Country
- ADCT Switzerland
- EHAB United States
- Employees
- ADCT N/A
- EHAB N/A
- Industry
- ADCT Biotechnology: Pharmaceutical Preparations
- EHAB Hospital/Nursing Management
- Sector
- ADCT Health Care
- EHAB Health Care
- Exchange
- ADCT Nasdaq
- EHAB Nasdaq
- Market Cap
- ADCT 454.5M
- EHAB 403.5M
- IPO Year
- ADCT 2020
- EHAB N/A
- Fundamental
- Price
- ADCT $4.40
- EHAB $9.01
- Analyst Decision
- ADCT Strong Buy
- EHAB Buy
- Analyst Count
- ADCT 6
- EHAB 2
- Target Price
- ADCT $7.60
- EHAB $9.00
- AVG Volume (30 Days)
- ADCT 759.6K
- EHAB 534.8K
- Earning Date
- ADCT 11-10-2025
- EHAB 11-05-2025
- Dividend Yield
- ADCT N/A
- EHAB N/A
- EPS Growth
- ADCT N/A
- EHAB N/A
- EPS
- ADCT N/A
- EHAB N/A
- Revenue
- ADCT $75,209,000.00
- EHAB $1,047,800,000.00
- Revenue This Year
- ADCT $11.78
- EHAB $4.95
- Revenue Next Year
- ADCT $4.83
- EHAB $4.51
- P/E Ratio
- ADCT N/A
- EHAB N/A
- Revenue Growth
- ADCT 6.35
- EHAB 1.02
- 52 Week Low
- ADCT $1.05
- EHAB $6.47
- 52 Week High
- ADCT $4.80
- EHAB $10.91
- Technical
- Relative Strength Index (RSI)
- ADCT 58.45
- EHAB 68.63
- Support Level
- ADCT $3.95
- EHAB $7.87
- Resistance Level
- ADCT $4.29
- EHAB $8.39
- Average True Range (ATR)
- ADCT 0.28
- EHAB 0.34
- MACD
- ADCT 0.03
- EHAB 0.10
- Stochastic Oscillator
- ADCT 89.02
- EHAB 98.96
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About EHAB Enhabit Inc.
Enhabit Inc provides home health and hospice services in the United States. Its reportable segments are Home Health and Hospice. The Home Health segment includes a comprehensive range of Medicare-certified home nursing services for adult patients in need of care. These services include, among others, skilled nursing, physical, occupational, and speech therapy, medical social work, and home health aide services. The Hospice segment focuses on the quality of life for patients who are experiencing a life-limiting illness while treating the person and symptoms of the disease, rather than the disease itself. The company generates a majority of its revenue from the Home Health segment.